Dr. Thomas Joos

Qualifications and history:

Since 2013: Deputy Managing Director, NMI

2008 - 2014 Director Strategic Alliances, EDI GmbH, Reutlingen (part time)
 
2000 - 2017 Head of Biochemistry Department, NMI
 
1998 - 2000 Research Assistant, NMI
 
1994 – 1998: Postdoctoral research, Dept. of Cell Biology, Max Planck Institute for Developmental Biology, Tübingen
 
1994: Ph.D. degree (Dr. rer. nat), Dept. of Cell Biology, Max Planck Institute for Developmental Biology, Tübingen (under Prof. P. Hausen; Topic: "Integrin-α5 during early embroygenesis of Xenopus laevis"
 
04–08 1988: Molecular biology practical, Biochemistry Dept., the Brandeis University“(under Prof. Andrew Szent-Györgyi), Waltham, Massachusetts, USA
 
1984 – 1990: Study of Biochemistry, University of Tübingen

Dr. Joos is a member of the editorial board of "Drug Discovery Today", "Proteomics" and "Expert Review of Proteomics".
He is a member of the Scientific Advisory Board of the Plasma Proteomics Institute in Washington, DC, USA and a member of the Scientific Advisory Board of Myriad RBM Inc. in Austin, Texas, USA.

Dr. Joos is the author of >100 scientific papers. He is recognized worldwide as an expert and opinion leader in the technology field of biomarkers and their clinical applications and basic research.

Dr. Joos is co-founder of SIGNATOPE GmbH, Reutlingen. SIGNATOPE develops innovative protein tests with which biomarkers for organ damage and drug interactions can be detected in all pharma-relevant species.

 

Dr. Thomas Joos

Deputy Director
Diplom-Biochemiker
T +49 (0)7121 51530-844
F +49 (0)7121 51530-16

Publications

  • Application of Mass Spectrometry-Based Immunoassays for the Species- and Tissue-Specific Quantification of Banned Processed Animal Proteins in Feeds
    Steinhilber A, Schmidt F, Naboulsi W, Planatscher H, Niedzwiecka A, Zagon J, Braeuning A, Lampen A, Joos T, Poetz O
    Analytical Chemistry. 2019 Feb 27. doi: 10.1021/acs.analchem.8b04652 Epub ahead of print
  • Serum inflammatory profile for the discrimination of clinical subtypes in Parkinson’s disease
    Yilmaz R, Strafella A, Bernard A, Schulte C, van den Huevel L, Schneiderhan-Marra N, Knorpp T, Joos T, Leypoldt F, Geritz J, Hansen C, Apel A, Gasser T, Lang A, Berg D, Maetzler W, Marras C
    Front Neurol., 2018 Dec 21 DOI:/10.3389/fneur.2018.01123
  • Species Differentiation and Quantification of Processed Animal Proteins and Blood Products in Fish Feed Using an 8-Plex Mass Spectrometry-Based Immunoassay
    Steinhilber AE, Schmidt FF, Naboulsi W, Planatscher H, Niedzwiecka A, Zagon J, Braeuning A, Lampen A, Joos TO, Poetz O
    J Agric Food Chem. 2018 Oct 3;66(39):10327-10335. doi: 10.1021/acs.jafc.8b03934. Epub 2018 Sep 24.
  • Increased Energy Expenditure, Lipolysis and Hyperinsulinemia Confer Resistance to Central Obesity and Type 2 Diabetes in Mice Lacking Alpha2α-Adrenoceptors
    Ruohonen ST, Valve L, Tuomainen K, Ailanen L, Röyttä M, Manz G, Baur N, Joos TO, Savontaus E, Scheinin M
    Neuroendocrinology. 2018 Jul 24. doi: 10.1159/000492387. [Epub ahead of print]
  • Peptide-Based Sandwich Immunoassay for the Quantification of the Membrane Transporter Multidrug Resistance Protein
    Poetz O, Dieze T, Hammer H, Weiß F, Sommersdorf C, Templin MF, Esdar C, Zimmermann A, Stevanovic S, Bedke J, Stenzl A, Joos TO.
    Anal Chem. 2018 May 1;90(9):5788-5794. doi: 10.1021/acs.analchem.8b00152. Epub 2018 Apr 12.
  • Mass Spectrometry-Based Immunoassay for the Quantification of Banned Ruminant Processed Animal Proteins in Vegetal Feeds
    Steinhilber AE, Schmidt FF, Naboulsi W, Planatscher H, Niedzwiecka A, Zagon J, Braeuning A, Lampen A, Joos T, Poetz O
    Anal Chem. 2018 Mar 20;90(6):4135-4143. doi: 10.1021/acs.analchem.8b00120. Epub 2018 Mar 7.
  • Direct Quantification of Cytochromes P450 and Drug Transporters-A Rapid, Targeted Mass Spectrometry-Based Immunoassay Panel for Tissues and Cell Culture Lysates
    Weiß F, Hammer HS, Klein K, Planatscher H, Zanger UM, Norén A, Wegler C, Artursson P, Joos TO, Poetz O
    Drug Metab Dispos. 2018 Apr;46(4):387-396. doi: 10.1124/dmd.117.078626. Epub 2018 Jan 17.
  • Development and Validation of an Ultrasensitive Procalcitonin Sandwich Immunoassay
    Carcamo Yañez V, Göpfert J, Otto M, Tumani H, Peter A, Joos T
    High-Throughput. 2017; 6(4): 18. https://doi.org/10.3390/ht6040018
  • Performance of a Multiplex Serological Helicobacter pylori Assay on a Novel Microfluidic Assay Platform
    Filomena A, Guenther A, Planatscher H, Topin F, She J, Formichella L, Terradot L, Gerhard M, Joos TO, Meyer H, Schneiderhan-Marra N
    Proteomes. 2017 Oct 3;5(4). pii: E24. doi: 10.3390/proteomes5040024.
  • Study of the Humoral Immune Response towards HCV Genotype 4 Using a Bead-Based Multiplex Serological Assay
    Filomena A, Göpfert JC, Duffy D, Pol S, Abdel-Hamid M, Esmat G, Fontanet A, Albert M, Joos T, Schneiderhan-Marra N
    High-Throughput. 2017; 6(4): 15.
  • Development of a Bead-Based Multiplex Assay for the Analysis of the Serological Response against the Six Pathogens HAV, HBV, HCV, CMV, T. gondii, and H. pylori
    Filomena A, Pessler F, Akmatov M, Krause G, Duffy D, Gärtner B, Gerhard M, Albert M, Joos T, Schneiderhan-Marra N,
    High-Throughput. 2017; 6(4): 14.
  • Tau plasma levels in subjective cognitive decline: Results from the DELCODE study
    Muller S, Preische O, Gopfert JC, Yanez VAC, Joos TO, Boecker H, Duzel E, Falkai P, Priller J, Buerger K, Catak C, Janowitz D, Heneka MT, Brosseron F, Nestor P, Peters O, Menne F, Schipke CG, Schneider A, Spottke A, Fliessbach K, Kilimann I, Teipel S, Wagner M, Wiltfang J, Jessen F, Laske C
    Sci Rep. 2017 Aug 25;7(1):9529. doi: 10.1038/s41598-017-08779-0.
  • Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer
    Endt K, Goepfert J, Omlin A, Athanasiou A, Tennstedt P, Guenther A, Rainisio M, Engeler DS, Steuber T, Gillessen S, Joos T, Schiess R
    PLoS One. 2017 Aug 2;12(8):e0181557. doi: 10.1371/journal.pone.0181557. eCollection 2017.
  • Progesterone receptor membrane component 1 is phosphorylated upon progestin treatment in breast cancer cell
    Willibald M, Bayer G, Stahlhut V, Poschmann G, Stuhler K, Gierke B, Pawlak M, Seeger H, Mueck AO, Niederacher D, Fehm T, Neubauer H
    Oncotarget. 2017 Aug 2;8(42):72480-72493. doi: 10.18632/oncotarget.19819. eCollection 2017 Sep 22.
  • Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition
    Schelle J, Hasler LM, Gopfert JC, Joos TO, Vanderstichele H, Stoops E, Mandelkow EM, Neumann U, Shimshek DR, Staufenbiel M, Jucker M, Kaeser SA
    Alzheimers Dement. 2017 Jun;13(6):701-709. doi: 10.1016/j.jalz.2016.09.005. Epub 2016 Oct 14.
  • Inflammatory profile discriminates clinical subtypes in LRRK2-associated Parkinson's disease
    Brockmann K, Schulte C, Schneiderhan-Marra N, Apel A, Pont-Sunyer C, Vilas D, Ruiz-Martinez J, Langkamp M, Corvol JC, Cormier F, Knorpp T, Joos TO, Bernard A, Gasser T, Marras C, Schule B, Aasly JO, Foroud T, Marti-Masso JF, Brice A, Tolosa E, Berg D, Maetzler W
    Eur J Neurol. 2017 Feb;24(2):427-e6. doi: 10.1111/ene.13223.
  • Miniaturized Multiplexed Protein Binding Assays
    Templin MF, Poetz O, Schwenk JM, Stoll D, Joos TO
    W.-L. Xing and J. Cheng. Frontiers in Biochip Technology. Boston, MA: Springer US; 2006. 61-87.
  • Bulk cell density and Wnt/TGFbeta signalling regulate mesendodermal patterning of human pluripotent stem cells
    Kempf H, Olmer R, Haase A, Franke A, Bolesani E, Schwanke K, Robles-Diaz D, Coffee M, Gohring G, Drager G, Potz O, Joos T, Martinez-Hackert E, Haverich A, Buettner FF, Martin U, Zweigerdt R
    Nat Commun. 2016 Dec 9;7:13602. doi: 10.1038/ncomms13602.
  • Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition
    Schelle J, Hasler L, Gopfert JC, Joos TO, Vanderstichele H, Stoops E, Mandelkow EM, Neumann U, Shimshek DR, Staufenbiel M, Jucker M, Kaeser SA
    Alzheimers Dement. 2017 Jun;13(6):701-709. doi: 10.1016/j.jalz.2016.09.005. Epub 2016 Oct 14.
  • Plasma matrix metalloproteinase 2 levels and breast cancer risk
    Aroner SA, Rosner BA, Tamimi RM, Tworoger SS, Baur N, Joos TO, Hankinson SE
    Cancer Epidemiol. 2015 Jun;39(3):321-7. doi: 10.1016/j.canep.2015.02.010. Epub 2015 Mar 19.
  • Selective p38alpha MAP kinase/MAPK14 inhibition in enzymatically-modified LDL-stimulated human monocytes: implications for atherosclerosis
    Cheng F, Twardowski L, Fehr S, Aner C, Schaeffeler E, Joos T, Knorpp T, Dorweiler B, Laufer S, Schwab M, Torzewski M
    FASEB J. 2017 Feb;31(2):674-686. doi: 10.1096/fj.201600669R. Epub 2016 Nov 8.
  • Coordinate regulation of Cyp2e1 by beta-catenin- and hepatocyte nuclear factor 1alpha-dependent signaling
    Groll N, Petrikat T, Vetter S, Colnot S, Weiss F, Poetz O, Joos TO, Rothbauer U, Schwarz M, Braeuning A
    Toxicology. 2016 Mar 28;350-352:40-8. doi: 10.1016/j.tox.2016.05.004. Epub 2016 May 3.
  • Coordinating Role of RXRalpha in Downregulating Hepatic Detoxification during Inflammation Revealed by Fuzzy-Logic Modeling
    Keller R, Klein M, Thomas M, Drager A, Metzger U, Templin MF, Joos TO, Thasler WE, Zell A, Zanger UM
    PLoS Comput Biol. 2016 Jan 4;12(1):e1004431. doi: 10.1371/journal.pcbi.1004431. eCollection 2016 Jan.
  • Impact of Feeding Strategies on the Scalable Expansion of Human Pluripotent Stem Cells in Single-Use Stirred Tank Bioreactors
    Kropp C, Kempf H, Halloin C, Robles-Diaz D, Franke A, Scheper T, Kinast K, Knorpp T, Joos TO, Haverich A, Martin U, Zweigerdt R, Olmer R
    Stem Cells Transl Med. 2016 Oct;5(10):1289-1301. Epub 2016 Jul 1.
  • Evaluation of novel biomarkers of nephrotoxicity in Cynomolgus monkeys treated with gentamicin
    Gautier JC, Zhou X, Yang Y, Gury T, Qu Z, Palazzi X, Leonard JF, Slaoui M, Veeranagouda Y, Guizon I, Boitier E, Filali-Ansary A, van den Berg BH, Poetz O, Joos T, Zhang T, Wang J, Detilleux P, Li B
    Toxicol Appl Pharmacol. 2016 Jul 15;303:1-10. doi: 10.1016/j.taap.2016.04.012. Epub 2016 Apr 19.
  • Inhibition of beta-catenin signaling by phenobarbital in hepatoma cells in vitro
    Groll N, Petrikat T, Vetter S, Wenz C, Dengjel J, Gretzmeier C, Weiss F, Poetz O, Joos TO, Schwarz M, Braeuning A
    Toxicology. 2016 Aug 31;370:94-105. doi: 10.1016/j.tox.2016.09.018. Epub 2016 Sep 30.
  • Inflammatory profile in LRRK2-associated prodromal and clinical PD
    Brockmann K, Apel A, Schulte C, Schneiderhan-Marra N, Pont-Sunyer C, Vilas D, Ruiz-Martinez J, Langkamp M, Corvol JC, Cormier F, Knorpp T, Joos TO, Gasser T, Schule B, Aasly JO, Foroud T, Marti-Masso JF, Brice A, Tolosa E, Marras C, Berg D, Maetzler W
    J Neuroinflammation. 2016 May 24;13(1):122. doi: 10.1186/s12974-016-0588-5.
  • A bead-based western for high-throughput cellular signal transduction analyses
    Treindl F, Ruprecht B, Beiter Y, Schultz S, Dottinger A, Staebler A, Joos TO, Kling S, Poetz O, Fehm T, Neubauer H, Kuster B, Templin MF
    Nat Commun. 2016 Sep 23;7:12852. doi: 10.1038/ncomms12852.
  • Phenobarbital inhibits calpain activity and expression in mouse hepatoma cells
    Groll N, Kollotzek F, Goepfert J, Joos TO, Schwarz M, Braeuning A
    Biol Chem. 2016 Jan 1;397(1):91-6. doi: 10.1515/hsz-2015-0223.
  • Selective, efficient modulation of activated CD4+ alphabetaT cells by the novel humanized antibody GZ-alphabetaTCR targeting human alphabetaTCR
    Blank G, Welker C, Haarer J, Sterk M, Nadalin S, Yanez VA, Joos TO, Menrad A, Snell D, LaCorcia G, Konigsrainer A, Handgretinger R, Schilbach K
    Bone Marrow Transplant. 2015 Mar;50(3):390-401. doi: 10.1038/bmt.2014.263. Epub 2014 Nov 17.
  • A Bead-Based Multiplex Sandwich Immunoassay to Assess the Abundance and Posttranslational Modification State of beta-Catenin
    Groll N, Sommersdorf C, Joos TO, Poetz O
    Methods Mol Biol. 2015;1295:441-53. doi: 10.1007/978-1-4939-2550-6_31.
  • Indirect protein quantification of drug-transforming enzymes using peptide group-specific immunoaffinity enrichment and mass spectrometry
    Weiß F, Schnabel A, Planatscher H, van den Berg BHJ, Serschnitzki B, Nuessler AK, Thasler WE, Weiss TS, Reuss M, Stoll D, Templin MF, Joos TO, Marcus K, Poetz O
    Sci Rep. 2015 Mar 4;5:8759. doi: 10.1038/srep08759.
  • Plasma matrix metalloproteinase 1, 3, and 7 levels and breast cancer risk in the Nurses' Health study
    Aroner SA, Rosner BA, Tamimi RM, Tworoger SS, Baur N, Joos TO, Hankinson SE
    Cancer Causes Control. 2014 Dec;25(12):1717-23. doi: 10.1007/s10552-014-0462-7. Epub 2014 Sep 16.
  • Identification of short terminal motifs enriched by antibodies using peptide mass fingerprinting
    Planatscher H, Weiss F, Eisen D, Zell A, Joos T, Poetz O
    Bioinformatics. 2014 May 1;30(9):1205-13. doi: 10.1093/bioinformatics/btu009. Epub 2014 Jan 9.
  • Development of a novel assay for proprotein converting enzyme activity on a multiplex bead-based array system
    Albrecht A, Rahmoune H, Leedjarv K, Knorpp T, Joos T, Stocki P, Guest PC, Bahn S
    Proteomics. 2013 Oct;13(20):2976-9. doi: 10.1002/pmic.201300060.
  • Catch and measure-mass spectrometry-based immunoassays in biomarker research
    Weiss F, van den Berg BH, Planatscher H, Pynn CJ, Joos TO, Poetz O
    Biochim Biophys Acta. 2014 May; 1844(5);927-932. doi: 10.1016/j.bbapap.2013.09.010.
  • From spots to beads-PTM-peptide bead arrays for the characterization of anti-histone antibodies
    Heubach Y, Planatscher H, Sommersdorf C, Maisch D, Maier J, Joos TO, Templin MF, Poetz O
    Proteomics. 2013 Mar;13(6):1010-5. doi: 10.1002/pmic.201200383.
  • Plasma levels of soluble glycoprotein VI (sGPVI) are associated with ischemic stroke
    Wurster T, Poetz O, Stellos K, Kremmer E, Melms A, Schuster A, Nagel E, Joos T, Gawaz M, Bigalke B
    Platelets. 2013;24(7):560-5. doi: 10.3109/09537104.2012.746455. Epub 2012 Dec 5.
  • Concurrent epigenetic silencing of wnt/beta-catenin pathway inhibitor genes in B cell chronic lymphocytic leukaemia
    Moskalev EA, Luckert K, Vorobjev IA, Mastitsky SE, Gladkikh AA, Stephan A, Schrenk M, Kaplanov KD, Kalashnikova OB, Poets O, Joos TO, Hoheisel JD
    BMC Cancer. 2012 Jun 6;12:213. doi: 10.1186/1471-2407-12-213.
  • Characterization of immunologically active drugs in a novel organotypic co-culture model of the human gut and whole blood
    Schmohl M, Schneiderhan-Marra N, Baur N, Hefner K, Blum M, Stein GM, Joos TO, Schmolz M
    Int Immunopharmacol. 2012 Oct 24;14(4):722-728. doi: 10.1016/j.intimp.2012.10.010.
  • Combining ultracentrifugation and peptide termini group-specific immunoprecipitation for multiplex plasma protein analysis
    Volk S, Schreiber TD, Eisen D, Wiese C, Planatscher H, Pynn CJ, Stoll D, Templin MF, Joos TO, Poetz O
    Mol Cell Proteomics. 2012 Jul;11(7):O111.015438. Epub 2012 Apr 23.
  • A dual array-based approach to assess the abundance and posttranslational modification state of signaling proteins
    Luckert K, Gujral TS, Chan M, Sevecka M, Joos TO, Sorger PK, Macbeat G, Poetz O
    Sci Signal. 2012 Jan 10;5(206):pl1. doi: 10.1126/scisignal.2002372.
  • Receptor tyrosine kinase inhibitor profiling using bead-based multiplex sandwich immunoassays
    Poetz O, Schneiderhan-Marra N, Henzler T, Herget T, Joos TO
    Methods Mol Biol. 2012;795:191-202. doi: 10.1007/978-1-61779-337-0_13.
  • A Miniaturized Ligand Binding Assay for EGFR
    Schwenk JM, Poetz O, Zeillinger R, Joos T
    Int J Proteomics. 2012; 2012: 247059. doi: 10.1155/2012/247059
  • A biomarker panel to discriminate between systemic inflammatory response syndrome and sepsis and sepsis severity
    Punyadeera C, Schneider EM, Schaffer D, Hsu HY, Joos TO, Kriebel F, Weiss M, Verhaegh WF
    J Emerg Trauma Shock. 2010 Jan;3(1):26-35. doi: 10.4103/0974-2700.58666
  • A generic operational strategy to qualify translational safety biomarkers
    Matheis K, Laurie D, Andriamandroso C, Arber N, Badimon L, Benain X, Bendjama K, Clavier I, Colman P, Firat H, Goepfert J, Hall S, Joos T, Kraus S, Kretschmer A, Merz M, Planatscher H, Schneiderhan-Marra N
    Drug Discov Today. 2011 July; 16(13-14): 600-608. DOI 10.1016/j.drudis.2011.04.011
  • Sandwich Immunoassay for Soluble Glycoprotein VI in Patients with Symptomatic Coronary Artery Disease
    Bigalke B, Poetz O, Kremmer E, Geisler T, Seizer P, Puntmann VO, Phinikaridou A, Chiribiri A, Nagel E, Botnar RM, Joos T, Gawaz M
    Clin Chem. 2011 Jun;57(6):898-904. Epub 2011 Apr 7. DOI: 10.1373/clinchem.2010.158527
  • Molecular indicators of non-sentinel node status in breast cancer determined in preoperative biopsies by multiplexed sandwich immunoassays
    Sauer G, Schneiderhan-Marra N, Muche R, Koretz K, Kazmaier C, Kreienberg R, Joos T, Deissler H
    J Cancer Res Clin Oncol. 2011 Aug;137(8):1175-84. Epub 2011 Apr 24.
  • Snapshots of protein dynamics and posttranslational modifications in one experiment - [beta]-catenin and its functions
    Luckert K, Goetschel F, Sorger PK, Hecht A, Joos TO, Poetz O
    Mol Cell Proteomics. 2011 May;10(5):M110.007377. Epub 2011 Mar 4. doi: 10.1074/mcp.M110.007377
  • Sequential multiplex analyte capturing for phospho-protein profiling
    Poetz O, Henzler T, Hartmann M, Kazmaier C, Templin MF, Herget T, Joos TO
    Mol Cell Proteomics. 2010 Nov;9(11):2474-81. Epub 2010 Aug 3. doi: 10.1074/mcp.M110.002709
  • Targeting peptide termini - a novel immunoaffinity approach to reduce complexity in mass spectrometric protein identification
    Hoeppe S, Schreiber TD, Planatscher H, Zell A, Templin MF, Stoll D, Joos TO, Poetz O
    Mol Cell Proteomics. 2011 Feb;10(2):M110.002857. doi: 10.1074/mcp.M110.002857. Epub 2010 Oct 20.
  • Sequential multiplex analyte capturing for phosphor-protein profiling
    Poetz O, Henzler T, Hartmann M, Kazmaier C, Templin MF, Herget T, Joos TO
    Mol Cell Proteomics. 2010 Nov; 9(11): 2474–2481. Published online 2010 Aug 3. doi: 10.1074/mcp.M110.002709
  • Optimal selection of epitopes for TXP-immunoaffinity mass spectrometry
    Planatscher H, Supper J, Poetz O, Stoll D, Joos T, Templin MF, Zell A
    Algorithms Mol Biol. 2010 Jun 25;5:28. doi: 10.1186/1748-7188-5-28
  • Multiplexed immunoassays for the analysis of breast cancer biopsies
    Schneiderhan-Marra N, Sauer G, Kazmaier C, Hsu HY, Koretz K, Deissler H, Joos TO
    Anal Bioanal Chem. 2010 Aug;397(8):3329-38. doi: 10.1007/s00216-010-3873-7. Epub 2010 Jul 18.
  • Protein microarrays for personalized medicine
    Yu X, Schneiderhan-Marra N, Joos TO
    Clin Chem. 2010 Mar;56(3):376-87. Epub 2010 Jan 14. doi: 10.1373/clinchem.2009.137158
  • Protein-protein-interactions in a multiplexed, miniaturized format a functional analysis of Rho GTPase activation and inhibition
    Schmohl M, Rimmele S, Potz O, Kloog Y, Gierschik P, Joos TO, Schneiderhan-Marra N
    Proteomics. 2010 Apr;10(8):1716-20. doi: 10.1002/pmic.200900597.
  • Bead-based protein-protein interaction assays for the analysis of Rho GTPase signaling
    Rimmele S, Gierschik P, Joos TO, Schneiderhan-Marra N
    J Mol Recognit. 2010 Nov-Dec;23(6):543-50. doi: 10.1002/jmr.1051.
  • Protein microarrays for diagnostic assays.
    Hartmann M, Roeraade J, Stoll D, Templin MF, Joos TO
    Anal Bioanal Chem. 2009 Mar;393(5):1407-16. Epub 2008 Sep 20. doi: 10.1007/s00216-008-2379-z.
  • Regulation of platelet glycoprotein VI (GPVI) surface expression and of soluble GPVI in patients with atrial fibrillation (AF) and acute coronary syndrome (ACS)
    Bigalke B, Stellos K, Weig HJ, Geisler T, Seizer P, Kremmer E, Potz O, Joos T, May AE, Lindemann S, Gawaz M
    Basic Res Cardiol. 2009 May;104(3):352-7. Epub 2009 Feb 3. doi: 10.1007/s00395-009-0779-7.
  • Multiplex microsphere-based flow cytometric platforms for protein analysis and their application in clinical proteomics - from assays to results
    Hsu HY, Joos TO, Koga H
    Electrophoresis. 2009 Dec;30(23):4008-19. doi: 10.1002/elps.200900211.
  • Protein microarrays: potentials and limitations
    Joos T, Bachmann J
    Front Biosci. 2009 Jan 1;14:4376-85.
  • Array-Technologien für die Multiparameteranalytik von Proteomen
    Herget T, Henzler T, Hayes S, Joos T
    2008. in: Schierack, Schröder. Mulitplex-DNA Mikropartikelpartien und deren Anwendung. Pabst Science Publishers. 3 - 15.
  • Proteome wide screening using peptide affinity capture
    Poetz O, Hoeppe S, Templin MF, Stoll D, Joos TO
    Proteomics. 2009 Mar;9(6):1518-23. doi: 10.1002/pmic.200800842.
  • Non-contact protein microarray fabrication using a procedure based on liquid bridge formation.
    Hartmann M, Sjödahl J, Stjernström M, Redeby J, Joos T, Roeraade J
    Anal Bioanal Chem. 2009 Jan;393(2):591-8. Epub 2008 Nov 21. doi: 10.1007/s00216-008-2509-7
  • Vitreous Levels of Bevacizumab and Vascular Endothelial Growth Factor-A in Patients with Choroidal Neovascularization.
    Zhu Q, Ziemssen F, Henke-Fahle S, Tatar O, Szurman P, Aisenbrey S, Schneiderhan-Marra N, Xu X, Bevacizumab T, Grisanti S
    Ophthalmology. 2008 Oct;115(10):1750-5, 1755.e1. doi: 10.1016/j.ophtha.2008.04.023. Epub 2008 Aug 16.
  • Miniaturized parallelized sandwich immunoassays
    Hsu HY, Wittemann S, Joos TO
    Methods Mol Biol. 2007;428:247-62.
  • Suspension microarrays for the identification of the response patterns in hyperinflammatory diseases
    Hsu HY, Wittemann S, Schneider EM, Weiss M, Joos TO
    Med Eng Phys. 2008 Oct;30(8):976-83. Epub 2008 Mar 3. doi: 10.1016/j.medengphy.2008.01.003
  • Pathogen specific cytokine release reveals an effect of TLR2 Arg753Gln during Candida sepsis in humans
    Woehrle T, Du W, Goetz A, Hsu HY, Joos TO, Weiss M, Bauer U, Brueckner UB, Marion Schneider E
    Cytokine. 2008 Mar;41(3):322-9. Epub 2008 Jan 30. doi: 10.1016/j.cyto.2007.12.006
  • New frontiers in microarray technology development
    Joos T, Kroeger P
    Curr Opin Biotechnol. 2008 Feb;19(1):1-3. doi: 10.1016/j.copbio.2007.12.001. Epub 2008 Jan 18.
  • Expanding assay dynamics: a combined competitive and direct assay system for the quantification of proteins in multiplexed immunoassays
    Hartmann M, Schrenk M, Dottinger A, Nagel S, Roeraade J, Joos TO, Templin MF
    Clin Chem. 2008 Jun;54(6):956-63. Epub 2008 Apr 24. doi: 10.1373/clinchem.2007.099812
  • Prediction of Nodal Involvement in Breast Cancer Based on Multiparametric Protein Analyses from Preoperative Core Needle Biopsies of the Primary Lesion.
    Sauer G, Schneiderhan-Marra N, Kazmaier C, Hutzel K, Koretz K, Muche R, Kreienberg R, Joos T, Deissler H
    Clin Cancer Res. 2008 Jun 1;14(11):3345-3353. doi: 10.1158/1078-0432.CCR-07-4802.
  • A Cryptic Vascular Endothelial Growth Factor T-Cell Epitope: Identification and Characterization by Mass Spectrometry and T-Cell Assays
    Weinzierl AO, Maurer D, Altenberend F, Schneiderhan-Marra N, Klingel K, Schoor O, Wernet D, Joos T, Rammensee HG, Stevanovic S (2008)
    Cancer Res. 2008 Apr 1;68(7):2447-54. doi: 10.1158/0008-5472.CAN-07-2540
  • Increasing robustness and sensitivity of protein microarrays through microagitation and automation.
    Hartmann M, Toegl A, Kirchner R, Templin MF, Joos TO
    Anal Chim Acta. 2006 Mar 30;564(1):66-73. Epub 2006 Feb 21. DOI: 10.1016/j.aca.2006.01.041
  • Current perspectives in protein array technology
    Kricka LJ, Master SR, Joos TO, Fortina P
    Ann Clin Biochem. 2006 Nov ; 43 (PT 6): 457-67.
  • Caspase-3 activation, Bcl-2 contents, and soluble FAS-ligand are not related to the inflammatory marker profile in patients with sepsis and septic shock
    Kriebel F, Wittemann S, Hsu HY, Joos T, Weiss M, Schneider EM
    Ann N Y Acad Sci. 2006 Dec ; 1090: 168-76. DOI: 10.1196/annals.1378.018
  • The long and difficult road to the diagnostic market: protein microarrays.
    Joos TO, Berger H
    Drug Discov Today. 2006 Nov;11(21-22):959-61. Epub 2006 Oct 2. DOI: 10.1016/j.drudis.2006.09.014
  • Protein Microarrays - Neue Systeme für die Proteomforschung
    Joos TO, Pawlak M, Templin M, Stoll D
    GIT Labor-Fachzeitschrift. 2006; 10, page 890-892.
  • Guidelines for terminology for microtechnology in clinical laboratories.
    Wilding P, Joos T, Kricka LJ, Shi L
    Pure Appl. Chem. 2006; 78(3): 677-684. doi:10.1351/pac200678030677
  • Protein microarrays: applications and future challenges
    Stoll D, Templin MF, Bachmann J, Joos TO
    Curr Opin Drug Discov Devel. 2005 Mar;8(2):239-52.
  • Protein Microarrays - A Promising Tool for Cancer Diagnosis
    Schneiderhan-Marra N, Kirn A, Döttinger A, Templin M, Sauer G, Deissler H, Joos TO
    Cancer Genomics & Proteomics. 2005 Jan; 2(1): 37-42.
  • Protein biochips: the calm before the storm.
    Bodovitz S, Joos T, Bachmann J
    Drug Discov Today. 2005 Feb 15; 10(4): 283-287. DOI: 10.1016/S1359-6446(05)03373-8
  • Protein microarrays: catching the proteome.
    Poetz O, Schwenk JM, Kramer S, Stoll D, Templin MF, Joos TO
    Mech Ageing Dev. 2005 Jan;126(1):161-70. DOI: 10.1016/j.mad.2004.09.030
  • Protein microarrays for antibody profiling: Specificity and affinity determination on a chip.
    Poetz O, Ostendorp R, Brocks B, Schwenk JM, Stoll D, Joos TO, Templin MF
    Proteomics. 2005 Jun;5(9):2402-11. DOI: 10.1002/pmic.200401299
  • The proteomics bottleneck: strategies for preliminary validation of potential biomarkers and drug targets
    Bodovitz S, Joos T
    Trends Biotechnol. 2004 Jan;22(1):4-7. DOI: 10.1016/j.tibtech.2003.10.013
  • Protein microarrays and multiplexed sandwich immunoassays: what beats the beads?
    Templin MF, Stoll D, Bachmann J, Joos TO
    Comb Chem High Throughput Screen. 2004 May;7(3):223-9.
  • Microarray technology: an increasing variety of screening tools for proteomic research.
    Stoll D, Bachmann J, Templin MF, Joos TO
    DDT:Targets. 2004 Dec 15; 9(24): 10-7
  • Protein microarray technology
    Joos T
    Expert Rev Proteomics. 2004 Jun;1(1):1-3.
  • Protein microarrays: promising tools for proteomic research
    Templin MF, Stoll D, Schwenk JM, Pötz O, Kramer S, Joos TO
    Proteomics. 2003 Nov;3(11):2155-66.